FDA Adverse Event Other Summary report: N

SYNVISC ONE (HYLAN G-F 20) INJECTION

MDR report key: 2350861 · Received November 22, 2011

Report

Report Number
2246315-2011-00291
Event Type
Other
Date Received
November 22, 2011
Date of Event
October 1, 2011
Report Date
November 15, 2011
Manufacturer
GENZYME BIOSURGERY (RIDGEFIELD)
Product Code
MOZ
PMA / PMN Number
P940015
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
OTHER
Health Professional
N

Narratives

Additional Manufacturer Narrative · 1

MANUFACTURER'S COMMENT: THE BENEFIT-RISK RELATIONSHIP OF THE PRODUCT IS NOT AFFECTED BY THIS REPORT.

Description of Event or Problem · 1

CASE DESCRIPTION: SPONTANEOUS REPORT WAS RECEIVED ON (B)(6) 2011 FROM A (B)(6) YEAR OLD FEMALE PATIENT, INITIALS (B)(6) WITH OSTEOARTHRITIS. THE PATIENT'S MEDICAL HISTORY INCLUDED PHLEBITIS. ON (B)(6) 2011, THE PATIENT INITIATED SYNVISC-ONE (HYLAN G-F 20) 6 ML INJECTION ONCE IN THE LEFT KNEE. THE PRODUCT LOT NUMBER WAS NOT REPORTED. ONE WEEK AFTER RECEIVING THE INJECTION, SHE BEGAN EXPERIENCING INCREASED SWELLING, PAIN, DIFFICULTY IN WALKING AND CALF PAIN. THE X RAY OF THE LEFT KNEE AND DOPPLER OF THE CALF WERE PERFORMED ON THE ADVICE OF HER FAMILY PRACTITIONER, AS THE PATIENT HAD A HISTORY OF PHLEBITIS. THE RESULTS WERE NEGATIVE. SHE HAD BEEN ON BEDREST, USING ICE AND HEAT. SHE COULD NOT BEND THE KNEES ALSO. ON (B)(6) 2011, SHE VISITED HER ORTHOPEDIC HEALTH CARE PROFESSIONAL AND APPROXIMATELY 50 CC OF THE FLUID WAS DRAINED FROM THE KNEE AND SHE WAS GIVEN AN INJECTION OF DEPO MEDROL (METHYLPREDNISOLONE ACETATE). ALL LABS PERFORMED ON THE FLUID WERE NEGATIVE. BY (B)(6) 2011, HER KNEE ALMOST RETURNED TO NORMAL. NO ACTION WAS TAKEN WITH SYNVISC-ONE. THE OUTCOME OF THE EVENT OF CALF PAIN AND DIFFICULTY WALKING WAS NOT PROVIDED. CONCOMITANT MEDICATIONS WERE NOT PROVIDED. THE INTENSITY FOR ALL THE EVENTS WAS NOT PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 SYNVISC ONE (HYLAN G-F 20) INJECTION INTRA-ARTICULAR HYALURONIC ACID MOZ GENZYME BIOSURGERY (RIDGEFIELD) UNK UNK

Patients

Seq Age Sex Outcome Treatment
1 69 YR Required Intervention